Glaxo CEO: Game-Changing HIV Drugs Are on the Way

The transcript discusses GSK's recent achievements, including launching six products with significant sales growth. It highlights upcoming regulatory submissions for the Shingrix vaccine and a COPD medicine. The company is advancing HIV treatments and oncology projects, including a groundbreaking gene therapy. Despite Brexit uncertainties, GSK remains committed to the UK, investing in facilities to support new product supply chains. The UK is seen as a favorable business environment due to its research heritage, competitive tax policies, and access to talent.

What are the advantages of doing business in the UK according to the speaker?

What investments is GSK making to support their new products?